[go: up one dir, main page]

PT100424A - Processo e sistema de ensaio para a actividade da neurotrofina - Google Patents

Processo e sistema de ensaio para a actividade da neurotrofina Download PDF

Info

Publication number
PT100424A
PT100424A PT100424A PT10042492A PT100424A PT 100424 A PT100424 A PT 100424A PT 100424 A PT100424 A PT 100424A PT 10042492 A PT10042492 A PT 10042492A PT 100424 A PT100424 A PT 100424A
Authority
PT
Portugal
Prior art keywords
cell
bdnf
oligonucleotide
cells
neurotrophic factor
Prior art date
Application number
PT100424A
Other languages
English (en)
Portuguese (pt)
Inventor
Stephen P Squinto
George D Yancopoulos
Steven H Nye
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PT100424A publication Critical patent/PT100424A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
PT100424A 1991-07-03 1992-04-23 Processo e sistema de ensaio para a actividade da neurotrofina PT100424A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72878491A 1991-07-03 1991-07-03
US76267591A 1991-09-20 1991-09-20

Publications (1)

Publication Number Publication Date
PT100424A true PT100424A (pt) 1993-10-29

Family

ID=27111743

Family Applications (1)

Application Number Title Priority Date Filing Date
PT100424A PT100424A (pt) 1991-07-03 1992-04-23 Processo e sistema de ensaio para a actividade da neurotrofina

Country Status (9)

Country Link
EP (1) EP0593663A4 (fr)
JP (1) JPH06509333A (fr)
AU (1) AU2322392A (fr)
CA (1) CA2112799A1 (fr)
IE (1) IE921315A1 (fr)
IL (1) IL101683A0 (fr)
NZ (1) NZ242467A (fr)
PT (1) PT100424A (fr)
WO (1) WO1993000909A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025683A1 (fr) * 1992-06-12 1993-12-23 Massachusetts Institute Of Technology Gene empechant la mort cellulaire programmee
US6902732B2 (en) 1992-06-12 2005-06-07 Massachusetts Institute Of Technology Identification and characterization of a gene which protects cells from programmed cell death and uses therefor
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
ATE165097T1 (de) * 1993-05-28 1998-05-15 Cephalon Inc Anwendung von indolocarbazol-derivaten zur behandlung von prostataerkrankungen
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
US5602309A (en) * 1993-10-04 1997-02-11 University Of Kentucky Research Foundation Transgenic mice which overexpress nerve growth factor
US5599808A (en) * 1994-02-18 1997-02-04 Cephalon, Inc. Aqueous indolocarbazole solutions
AU715527B2 (en) * 1995-06-27 2000-02-03 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
US6274576B1 (en) 1995-06-27 2001-08-14 The Henry Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
US5859311A (en) * 1995-11-27 1999-01-12 University Of Kentucky Research Foundation Transgenic mice which overexpress neurotrophin-3 (NT-3) and methods of use
US6200968B1 (en) 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US7795246B2 (en) * 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
DK1624936T3 (da) * 2003-05-16 2010-03-15 Univ Laval CNS-chloridmodulering og anvendelser deraf
JP2007537167A (ja) 2004-05-14 2007-12-20 ユニヴェルシテ ラヴァル ホスホリパーゼｃガンマの調節、並びにそれによる疼痛及び侵害受容の制御
EP2294183B1 (fr) 2008-06-18 2015-12-16 The Texas A&M University System Cellules souches mésenchymateuses, compositions et procédés pour le traitement des lésions du tissu cardiaque
PL2825648T3 (pl) * 2012-03-15 2019-01-31 Curna, Inc. Leczenie chorób związanych z neurotroficznym czynnikiem pochodzenia mózgowego (bdnf) poprzez zahamowanie naturalnego transkryptu antysensownego względem bdnf
CN104602714A (zh) * 2012-05-16 2015-05-06 Rana医疗有限公司 用于调节bdnf表达的组合物和方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor

Also Published As

Publication number Publication date
JPH06509333A (ja) 1994-10-20
IE921315A1 (en) 1993-01-13
WO1993000909A1 (fr) 1993-01-21
EP0593663A4 (en) 1996-10-30
IL101683A0 (en) 1992-12-30
CA2112799A1 (fr) 1993-01-21
NZ242467A (en) 1995-06-27
AU2322392A (en) 1993-02-11
EP0593663A1 (fr) 1994-04-27

Similar Documents

Publication Publication Date Title
PT100424A (pt) Processo e sistema de ensaio para a actividade da neurotrofina
Moyer et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase
Erber et al. Combined inhibition of VEGF‐and PDGF‐signaling enforces tumor vessel regression by interfering with pericyte‐mediated endothelial cell survival mechanisms
KR0171210B1 (ko) 암치료용 항감작 올리고뉴클레오티드
Boyd et al. A dose‐dependent facilitation and inhibition of peripheral nerve regeneration by brain‐derived neurotrophic factor
Fabbro et al. PKC412-a protein kinase inhibitor with a broad therapeutic potential
US5990088A (en) Method for treating kaposi's sarcoma with antisense oligonucleotides
Noguchi et al. Survival and proliferative roles of erythropoietin beyond the erythroid lineage
DE60029138T2 (de) Verwendung von Indolinonverbindungen zur Herstellung von Pharmazeutika für die Modulation der Funktion c-kit Proteintyrosinkinase
US20210023116A1 (en) Treatment of cancer by systemic administration of dbait molecules
JP2004537517A (ja) ｃ−ｍｙｃアンチセンスオリゴマーを使用した、癌を処置するための併用アプローチ
PL199576B1 (pl) Zastosowanie jednego lub więcej N-podstawionych indolo-3-glioksylamidów lub ich fizjologicznie tolerowanych soli addycyjnych do wytwarzania leku do leczenia farmaceutycznie opornych nowotworów
Smith et al. Regional differences in the expression of corticostriatal synaptic plasticity
Takano et al. Suramin inhibits glioma cell proliferation in vitro and in the brain
JP2003500418A (ja) 多発性嚢胞腎疾患の処置のためのｃ−ｍｙｃに対するアンチセンス
WO2020234454A1 (fr) Traitement combiné contre le cancer ciblant le métabolisme énergétique et le ph intracellulaire
Fischer Nerve growth factor reverses spatial memory impairments in aged rats
CN113230249A (zh) 土荆皮乙酸在作为或制备Hedgehog信号通路抑制剂中的应用
JP2003506487A (ja) タンパク質チロシンホスファターゼインヒビター（ｐｔｐ）としてのペルオキソバナジウム化合物、血管形成、再狭窄およびエンドセリン産生に対するそれらの阻害作用、並びに免疫応答に対するそれらの刺激作用
CN111803489B (zh) 含笑内酯及其衍生物在垂体腺瘤治疗中的应用
CA2227370A1 (fr) Procedes pour tuer selectivement des cellules ou inhiber selectivement la croissance de cellules exprimant le gene waf1
TW200306200A (en) Use of long pentraxin PTX3 for the preparation of a medicine for the treatment of tumour diseases associated with abnormal activation of growth factor FGF-8
HUP0600841A2 (en) Non-nucleosidic inhibitors of reverse transcriptase as antagonists of cell proliferation and inducers of cell differentiation
US20250221967A1 (en) Compositions and methods for the treatment of cancer and other proliferative diseases
US20240141353A1 (en) Sirnas against kras and raf1

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19930323

FC3A Refusal

Effective date: 19990405